ATE162072T1 - Kleine partikeln enthaltende arzneistoffzusammensetzung - Google Patents

Kleine partikeln enthaltende arzneistoffzusammensetzung

Info

Publication number
ATE162072T1
ATE162072T1 AT90915978T AT90915978T ATE162072T1 AT E162072 T1 ATE162072 T1 AT E162072T1 AT 90915978 T AT90915978 T AT 90915978T AT 90915978 T AT90915978 T AT 90915978T AT E162072 T1 ATE162072 T1 AT E162072T1
Authority
AT
Austria
Prior art keywords
microspheres
composition containing
small particles
medicinal composition
containing small
Prior art date
Application number
AT90915978T
Other languages
English (en)
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10665744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE162072(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danbiosyst Uk filed Critical Danbiosyst Uk
Application granted granted Critical
Publication of ATE162072T1 publication Critical patent/ATE162072T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT90915978T 1989-11-04 1990-11-01 Kleine partikeln enthaltende arzneistoffzusammensetzung ATE162072T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8924935A GB2237510B (en) 1989-11-04 1989-11-04 Small particle drug compositions for nasal administration

Publications (1)

Publication Number Publication Date
ATE162072T1 true ATE162072T1 (de) 1998-01-15

Family

ID=10665744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90915978T ATE162072T1 (de) 1989-11-04 1990-11-01 Kleine partikeln enthaltende arzneistoffzusammensetzung

Country Status (10)

Country Link
EP (1) EP0500594B1 (de)
JP (1) JP2974409B2 (de)
AT (1) ATE162072T1 (de)
CA (1) CA2060176C (de)
DE (1) DE69031950T2 (de)
DK (1) DK0500594T3 (de)
ES (1) ES2112253T3 (de)
GB (1) GB2237510B (de)
GR (1) GR3026367T3 (de)
WO (1) WO1991006282A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
ES2108258T3 (es) * 1992-01-17 1997-12-16 Alfatec Pharma Gmbh Granulos que contienen sustancias medicamentosas peptidicas y su preparacion asi como su empleo.
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
WO1995034582A1 (en) * 1994-06-16 1995-12-21 Pharmacia S.P.A. Bioadhesive starches and process for their preparation
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6344202B1 (en) 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
AU760537B2 (en) * 1998-06-29 2003-05-15 Novartis Ag Particulate delivery systems and methods of use
EP1108423B1 (de) * 1998-08-26 2005-03-30 Teijin Limited Pulverförmige pernasale mittel
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2002060486A2 (en) * 2001-01-29 2002-08-08 Fresco Bernard B Controlled release microsphere system for administration of drug to the eye
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
CA2664427C (en) 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
BR112012002963A2 (pt) * 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9839617B2 (en) 2014-01-27 2017-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoencapsulation of hydrophilic active compounds
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520247A (en) * 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1520248A (en) * 1975-07-24 1978-08-02 Fisons Ltd Sodium cromoglycate containing medicament
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
EP0187433B1 (de) * 1983-08-01 1990-12-27 Teijin Limited Pulverige pharmazeutische Zusammensetzung zur Anwendung auf die Schleimhaut der Mund- oder Nasenhöhle
DE3341001A1 (de) * 1983-11-12 1985-05-23 Krause, Hans Jürgen Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system

Also Published As

Publication number Publication date
CA2060176A1 (en) 1991-05-05
JP2974409B2 (ja) 1999-11-10
DK0500594T3 (da) 1998-09-14
GR3026367T3 (en) 1998-06-30
EP0500594A1 (de) 1992-09-02
EP0500594B1 (de) 1998-01-14
GB2237510A (en) 1991-05-08
DE69031950T2 (de) 1998-05-28
JPH05501408A (ja) 1993-03-18
CA2060176C (en) 2001-01-09
WO1991006282A1 (en) 1991-05-16
GB8924935D0 (en) 1989-12-28
DE69031950D1 (de) 1998-02-19
ES2112253T3 (es) 1998-04-01
GB2237510B (en) 1993-09-15

Similar Documents

Publication Publication Date Title
DE69031950D1 (de) Kleine partikeln enthaltende arzneistoffzusammensetzung
US5876754A (en) Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
DE69428040D1 (de) Orale darreichungsform
DK0731688T3 (da) Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
DE3688674D1 (de) Hydroxypropylcelluloseether enthaltende mittel mit verzoegerter wirkstoffabgabe.
BR9909394A (pt) Composição de aerossol, composição farmacêutica, recipiente, dispositivo de inalação, processo para preparar uma composição de aerossol, mistura de um primeiro material particulado, e, processo para administrar um medicamento particulado
CA2116563A1 (en) Dry gel pharmaceutical composition
ATE155682T1 (de) Aerosolformulierung feste polypeptid mikroteilchen enthaltend und verfahren zu ihrer herstellung
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
KR890006252A (ko) 분말형 폴리펩타이드의 비강내 투여용 조성물 및 투여방법
ES2053549T3 (es) Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
NO306847B1 (no) Blanding for nasal administrering av nikotin
HUP0000520A2 (hu) Új vizes gyógyszerkészítmények hajtógázmentes aeroszolokhoz
YU46701B (sh) Postupak u za dobijanje osnovnog nosećeg materijala za dozne oblike lekova sa produženim izdvajanjem aktivne supstance
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
EP0513702A3 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
DE3770280D1 (de) Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha.
HRP20000867B1 (en) Pharmaceutical formulations for aerosols with two or more active substances
KR880004805A (ko) 분무건조된 아세트아미노펜
ID22763A (id) Komposisi penstabil tibolon
DE68905613D1 (de) Pharmazeutische zubereitung.
ES2058988T3 (es) Preparacion de medicamentos para el tratamiento sistemico de peces ornamentales y utiles.
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
RZN Patent revoked